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1Chapter
Intranasal Insulin as Promising 
Therapy for Preserving Pragmatic 
Competence in MCI and AD
Sara Schatz
Abstract
Our chapter contends that extended intranasal insulin administration can 
preserve pragmatic functioning even when there are temporal lobe and frontal lobe 
brain volume losses consistent with AD disease progression. CT scans of a patient 
receiving extended intranasal insulin 6 years after AD diagnosis are compared with 
his CT scans at the original MCI diagnosis. The results demonstrate that areas of 
the brain associated with pragmatic functioning were not as affected as expected in 
late-stage AD patients. This, along with linguistic evidence of preserved pragmatic 
competence, indicates the likely effectiveness of intranasal insulin treatment in 
enhancing neuronal activity in certain areas of the brain associated with pragmatic 
competence.
Keywords: MCI, intranasal insulin, brain atrophy, pragmatics
1. Introduction
This chapter explores, on a brain circuitry level, why patients receiving extended 
intranasal insulin therapy continue to be able to ambulate independently, pay atten-
tion, speak, and participate in jokes even throughout late-stage AD [1–3]. We find 
that extended intranasal insulin administration can preserve pragmatic functioning 
even when there are temporal lobe and frontal lobe volume losses consistent with 
Alzheimer’s brain (AD) volume loss. A series of CT scans of a patient receiving 
extended intranasal insulin from mild cognitive impairment (MCI) diagnosis and those 
from the same patient 5.5 years after AD diagnoses are examined. At baseline, this 
patient’s original MCI CT scans indicated no significant intracranial pathology and nor-
mal aging brain morphology. Over time, we show how this patient demonstrates slower 
atrophy rates in occipital and thalamic structures as compared with the structural 
imaging of patients with disease progression from MCI to AD not receiving intranasal 
insulin therapy. Enhancing neuronal activity in the areas of the brain associated with 
pragmatic competence reduces the likelihood of anomia typical of late-stage AD.
This chapter is structured as follows: Section 1 examines studies of the perfusion 
of intranasal insulin in older adults concerning neuropsychiatric tests of cognitive 
decline in MCI and AD. Section 2 discusses CT scans and the medical and social 
history of the patient case study used in this chapter. Section 3 examines CT scans at 
three distinctive points in the patient’s MCI to AD progression (at MCI diagnosis and 
3.5 and 5.5 years receiving intranasal insulin therapy). Section 4 suggests that results 
demonstrating extended intranasal insulin treatment may slow disease progression 
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by reducing some areas of neuronal atrophy in the (thalamus) cortico-pulvinar 
projection system associated with the anomia typical of late-stage AD.
2. The perfusion of intranasal insulin in context
In MCI and AD, the intranasal delivery of insulin has been found to enhance 
brain insulin activity either through improved glucose metabolism or reducing 
hypothalamic inflammation [4]. The route of intranasal insulin to the central 
nervous system (CNS) is via the olfactory and trigeminal neural pathways which 
innervate the nasal cavity and provide a direct connection to the CNS [5]. Given the 
short time frame (15–30 minutes) by which intranasal insulin reaches the brain, 
it is assumed that extracellular delivery from the nasal mucosa, instead of axonal 
transport, is the main transport mechanism. Glucose metabolism abnormality is 
thought to play a critical role in pathophysiological alterations by inducing multiple 
pathogenic factors such as oxidative stress, mitochondrial dysfunction, glycolysis, 
and Krebs citric acid cycle [6]. By pharmacologically restoring disrupted brain 
insulin signaling that ensues from glucose insufficiency [7], intranasal insulin is 
thought to promote neurol survival.1
Recent studies of the perfusion of intranasal insulin into the regional areas of the 
brain cortex demonstrate two main regional cortical areas of penetration. Akintola 
et al. [10] found that, in older adults, intranasal administration of insulin signifi-
cantly increased perfusion through the occipital gray matter by 6.5% (P = 0.001) 
when compared to the administration of placebo as well as perfusion into the 
thalamus (P = 0.003). Perfusion through the parietal gray matter was also increased 
by 4.3% after administration (P = 0.034) in older adults.
According to the authors, increased perfusion strongly suggests that intranasal 
insulin therapy might restore energy demand and neuronal activity in these regions. 
They note:
We observed that intranasal insulin application increased perfusion of the thala-
mus. The thalamus receives information from almost all sensory systems and relays 
the information to associated cortical areas. From literature, increased cerebral 
blood flow has been linked to vasodilatation around the active area due to increased 
energy demand [11]. Also, insulin has been shown to be a vasoactive modulator that 
regulates peripheral and cerebral blood flow possibly via a direct vasodilatory effect 
[12]. Taken together, our finding of increased perfusion in some brain areas would 
support the hypothesis that intranasal insulin application might restore energy 
demand and neuronal activity in these regions [4, 10].
2.1  The thalamus and occipital structures in language, attention, and 
visuospatial tasks in Alzheimer’s disease
The thalamus is a central mechanism in understanding and formulating 
language [13]. It passes information from one cortical area involved in language 
generation to another, including semantic feature binding and the generation of 
1 Delivery of IGF-I to the CNS is thought to be beneficial in the treatment of Alzheimer’s disease or 
stroke because of IGF-I’s ability to potently promote neuronal survival [8]. In adult rat CNS, regions of 
the circumventricular organs (choroid plexus and median eminence), olfactory system (olfactory bulb, 
anterior olfactory nucleus, and primary olfactory cortex), frontal cortex, hippocampus, amygdala, cer-
ebellum, and spinal gray matter exhibit the highest concentration of IGF-I binding sites [9]. In a recent 
study, Sami et al. show that intranasal insulin treatment moderately increases glucose uptake in the WT 
mouse hippocampus via activating the Akt2 signaling pathway.
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lexical items [14]. Pragmatics, in particular, relies on both the left and the right 
hemispheres, and the thalamus mediates from the superior temporal cortex and 
posterior parietal cortex, or the “language eloquent cortex” in humans [15, 16].
The thalamus is also relevant to “cognition,” which includes the capacity to pay 
attention and to process multiple channels of information at once, i.e., to engage in 
“intentionally guided attention” or “engagement in action” [17]. An explicit mecha-
nistic model has even been developed for thalamic stimulation effects on language 
and cognition that incorporate modern activation and connectivity data called the 
“specific alerting response” (SAR). The SAR effect involves secondary switching 
in the striatum caused by the activation of thalamostriatal projections, whereas the 
“anomia effect” implicates the disruption of the cortical synchronization action of 
the pulvinar via the cortico-pulvinar-cortical projection system [18].2 In this SAR 
model, the retained ability to speak (an “anti-anomic” effect) depends upon the pres-
ervation of nuclei within the thalamus to regulate the transmission of information to 
the cortex and between cortical areas [21]. As such, the thalamus acts as a “selective 
engagement mechanism” which suppresses right frontal cortical activity, preventing 
it from interfering with language [17]. As Crosson [22] notes:
“in other words, once an intention to act is formed, the frontal lobes engage the 
cortical nets relevant to the intended activity. For example, if one intends to engage 
in a conversation, frontal cortex associated with language, via the nucleus reticu-
laris and the pulvinar, engages cortices related to understanding and formulating 
language. At the same time, areas not involved in the intended activity would be 
held in a state of relative disengagement so as to minimize attention to stimuli 
irrelevant to the intended task.”
In Alzheimer’s disease, it is well recognized that the thalamus is essential 
for generating attention [23], and its anterior and medial nuclei are involved in 
declarative memory functioning [24]. Anatomic evidence from AD patients shows 
that thalamic volume reduction in Alzheimer’s disease has been related not only 
to anomia but also to global cognitive decline in all of these areas: motor behavior, 
emotional, motivational, associative, and cognitive abilities [25]. Nevertheless, 
until de Jong et al. [26], the direct correlation between measurements of decreasing 
thalamic volume and cognitive functioning in Alzheimer’s disease had never been 
reported in the literature.
Intranasal administration of insulin also significantly increased perfusion 
through the occipital and parietal gray matter in older adults [10]. The occipital lobe 
is the visual processing center of the mammalian brain containing most of the ana-
tomical region of the primary visual cortex. It also contains the ventral stream of 
vision that enables ability to focus on motor actions in response to outside stimuli. 
The parietal lobe is a source of speech and reading. Next to the occipital lobe, the 
parietal lobe integrates sensory information among various modalities, including 
proprioception, mechanoreception, and visuospatial processing. The posterior 
parietal cortex, also referred to as the dorsal stream of vision, receives somatosen-
sory and/or visual input that can be transmitted to motor signals [27].
In MCI and AD, impairments in the dorsal stream of visual perception and 
processing have been found to be a predictor of AD [28]. Increasing impairment 
in visuospatial skills, visual object processing, and visual recognition of human 
2 The functional and anatomic evidence supports the assertion that the connectivity of the pulvinar 
is the likely nucleus to mediate communication of information [18]. The pulvinar is heavily connected 
to the cortex and forms cortico-thalamo-cortical pathways. As a general principle, directly connected 
cortical areas will be indirectly connected via the pulvinar [19, 20].
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emotion processing are common on test scores of AD patients as part of annual 
cognitive deterioration [29–31]. Previous studies of MCI and AD patients receiv-
ing extended intranasal insulin have demonstrated unusual patterns of relatively 
limited annual cognitive declines as measured by several years of neuropsychiat-
ric batteries. This was the case in tests covering visuospatial skills and executive 
function and inference tests which required simultaneous attention and the pro-
cessing of multiple sources of information in parallel such as the VOSP Number 
Location, Pentagons, Modified Rey, CATS-Fact, and Affect Matching tests [2]. 
Furthermore, the short-term administration of intranasal insulin (21 days) has 
been found to significantly improve response inhibition on discordant items of  
an executive function-attention test (the Stroop test) [32, 33]. In addition, visuo-
spatial function was significantly improved in performance on the Benton Visual 
Retention Test (BVRT) after 40 IU of insulin detemir, regardless of apoe4 status 
[32, 34].
Observational data on one patient receiving extended intranasal insulin therapy 
showed that even 5.5 years after AD diagnosis, he was still able to walk indepen-
dently, pay attention to his physical surroundings, process visual information, and 
make verbal inferences [2]. Another patient who began intranasal insulin at MCI/
mild dementia diagnosis after having lost the ability to manage his finances, shop, 
or independently go to doctor’s visits returned to being able to do all of these tasks 
and even to going skiing after 3 years on treatment.
3. CT scans and progression from MCI to AD
Computed tomography (CT) is a structural medical imaging method that 
employs computer-based tomographic reconstruction to delineate bodily structures 
based on their ability to block X-ray beams. CT images are used to identify struc-
tural abnormalities, such as space-occupying lesions or intracranial neoplasms, 
although CT images are less fine in detail than newer structural imaging technolo-
gies [35].
The key CT structural markers of disease development in the progression from 
MCI to AD include atrophy rate measurements in the hippocampus and medial 
temporal lobe (the inner part of the temporal lobe, near the divide between the left 
and right hemispheres) [36]. In addition, ventricular enlargement of portions of 
the lateral ventricles adjacent to the medial temporal lobe (MTL) is also a sensitive 
marker of the transition from MCI to AD [37–39]. Thus, in the disease progression 
from MCI to AD, hypometabolism in glucose uptake leads to increased atrophy rates 
of lateral ventricles adjacent to the MTL and to a reduction of hippocampal volume 
and then to the temporal neocortex. Finally, the disease progresses into adjoining 
association and primary sensory areas [40, 41].
The medial temporal lobe in particular is thought to be involved in declarative 
and episodic memory. Deep inside the medial temporal lobe is the region of the 
brain which includes the hippocampus, the amygdala, the cingulate gyrus, the 
thalamus, the hypothalamus, the epithalamus, the mammillary body, and other 
organs, many of which are of particular relevance to the processing of memory. 
Studies of single-dose intranasal insulin demonstrate that intranasal does reach 
the hypothalamus but these results did not reach statistically significant levels 
([10]:793). Other single-dose studies of intranasal insulin to diabetics showed 
acutely increased resting-state functional connectivity between the hippocampal 
regions and multiple regions within the DMN, i.e., the medial frontal cortex; the 
medial, lateral, and inferior parietal cortex (IPC); and anterior (ACC) and posterior 
cingulate cortex (PCC). These are brain regions directly linked to interactive higher 
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cognitive functions [42]3 including language. The uncus,4 an anterior extremity 
of the parahippocampal gyrus, a deep structure within the limbic system of the 
MTL, is of central importance in protecting/rescuing hippocampal neurons from 
amyloid-induced neurotoxicity [43, 45, 46].
Conversely, patients on extended intranasal insulin should demonstrate slower 
rates of atrophy as the insulin restores energy demand and neuronal activity in 
occipital and parietal gray matter regions and the thalamus [10]. CT scans over 
the AD disease course of a patient receiving extended intranasal insulin can be 
hypothesized to illustrate patterns closer to “normal aging” of MCI even 5–6 years 
after AD diagnosis (see also Additional materials). Thus, it can be hypothesized 
that AD patients receiving extended intranasal insulin therapy may demonstrate 
slower atrophy rates in occipital and thalamic structures than MCI to AD patients 
not receiving this therapy.
3.1 Case study: social and medical history
A series of three CT scans were conducted on patient “AR” between May 
2012 and April 2018. AR was between the ages of 82 and 88 during this time and 
was being treated by a Kaiser Permanente Neurologist who diagnosed him with 
Alzheimer’s disease in December 2012 after a May 2012 diagnosis of mild cogni-
tive impairment. The patient was moved out of state in September 2017 when his 
82-year-old girlfriend developed Parkinson’s disease. He subsequently lived near his 
daughter in an Alzheimer facility and was seen by a qualified university neurologist 
until his death in December 2018.
The patient initially became involved in the compassionate use of twice-daily 
intranasal insulin for the purposes of reducing cognitive decline in June 2013. This 
treatment was administered by nurses who also gave him his daily medications and 
reminded the patient to conduct daily or weekly hygiene (bathing, tooth brushing, 
correct dressing). The patient ate independently or with minor assistance through-
out the course until the final months of his life when he needed assistance with 
cutting up his food (8/18–12/18). During the years of 2012–2017, AR was still able 
to live in his home with his 80-year-old girlfriend who cooked, shopped, and drove 
him to their social activities, and his financial and medical management was done 
3 Zhang et al. [42] found that intranasal insulin-treated diabetic subjects performed better on the 
visuospatial memory task (BVMT-R) and on verbal fluency naming tasks. The former tended to correlate 
with stronger connectivity between the left hippocampal region and PCC. Better performance on the 
verbal fluency naming task was associated with stronger coefficient of connectivity between the right 
hippocampal region and ACC and lesser connectivity between the left hippocampal regions and the MFC 
for a more difficult category switching task. As Zhang et al. [42] summarize: “Differences in relation-
ships between cognition and connectivity between the right and left hippocampal regions were found 
which reflect a complexity of the large-scale verbal fluency network that comprises of verbal fluency 
and orthographic discrimination subnetworks…Set switching is a complex operation involving a number 
of different brain structures that usually include various parts of the dorsolateral and dorsomedial 
prefrontal cortex, as well as temporal regions where hippocampus is located.”
4 The uncus is a rudimentary, small area where the frontal lobe meets the temporal lobe and the area of 
cortex on the uncus of the parahippocampal gyrus (both belonging to the olfactory cortex). It is phylo-
genetically older (the so-called paleocortex) and is part of the limbic system. The uncus is connected to 
the olfactory tract through nerve fibers which bend abruptly toward it and is separated from the apex 
of the temporal lobe by a slight fissure called the incisura temporalis. Given its centrality in early MCI 
[43], it is necessary to ascertain potential structural and/or diffusional and cellular barriers to intranasal 
insulin penetration into the surrounding CNS tissue and significant clearance of CSF into the venous and 
lymphatic circulation [44].
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by his daughter [2]. While residing in his Alzheimer residence facility (11/17–12/18), 
AR was still ambulatory, fed himself, ate with the early AD patients at the dining 
room, and was highly conversational even at this stage of disease progression [3].
AR’s medical history at MCI diagnosis was (5/12) OSA, diverticulosis, tinnitus, 
lumbar stenosis, and BPH. His medications were memantine, donepezil, tamsulo-
sin, multivitamin, and intranasal insulin (at 6/13). At 10/16, the same medications, 
all blood work normal.5 At 4/18, the same medications, all blood work normal. At 
4/18, 5.5 years after his original AD diagnosis and at age 88, his doctor stated to AR’s 
daughter that the patient was still “very functional with good language skills” and, 
to the doctor’s surprise, still possessed “the body of a 70-year-old” [3].
4. Results
4.1 At MCI diagnosis: before beginning intranasal insulin therapy
AR was diagnosed with MCI in May 2012 based on a Slums test score (24/30) 
and a mild cognitive impairment AD8 score = 0/8. His neurologists stated: “The 
patient came in because he had begun to not remember essential tasks, lost his keys 
and had begun to become disoriented at times. For example, he could not remem-
ber the proper freeway exit for the airport or where he was on the freeway despite 
having driven to that airport on that same route for over 40 years. Patient himself 
feels memory not so good. He was also beginning to forget the names of plants at the 
botanical gardens which he once knew he could. His girlfriend thinks his memory 
issue may be out of the ordinary in forgetting day to day conversations [47].”
CT scans were ordered due to this “altered level of consciousness.” The initial CT 
findings of AR’s neurologist at this time stated there was “no significant intracranial 
pathology” with “normal aging brain morphology.” All other CT findings were also 
“normal,” i.e., “intact (calvarium, central skull base, temporal mastoids: adequate; 
cellular, non-sclerotic, paranasal sinuses: well aerated; brain showed no acute intra-
cranial bleed, large vessel territory infarct, or mass effect) (CT Results 5/12).”6 B-12 
and TSH levels were also in normal limits (5/12). Indeed, the overall assessment of 
AR’s 5/12 CT scan was summarized succinctly as “changes of aging brain.”
In terms of his memory loss, however, the neurologist’s findings were more 
uncertain. He noted: “Robust looking man. Gait brisk, very cordial and engaging 
and gives detailed history but when asked his profession, he seemed to have to think 
awhile before he recalled he was a science teacher.” Clearly AR’s neurologist detected 
something was amiss when he stated: “While patient score is in the mild cognitive 
impairment range, and while he is very intellectually active: plays bridge, studies 
German, goes folk dancing still I think he should be scoring higher than he does. 
While I cannot make a diagnosis of Alzheimer’s now, I think we need to follow up in 
6 months and see how it goes [47].”
Nevertheless, CT at 5/12 did show markers of disease progression toward 
AD. AR’s CT scan includes the following analysis: “Ventricles are ‘prominent’ as 
there are subarachnoid spaces within cerebrospinal fluid.” Ventricular enlargement 
represents a feasible short-term marker of disease progression in subjects with MCI 
5 Full blood work results available upon request. (10/16): BP 121/58 mmHg | Pulse 84 | Temp(Src) 98.7°F 
(37.1°C) | Resp 18 | Wt 189 lb. 6 oz. (85.9 kg) | SpO2 98%. Ext: WWP; no leg swelling/asymmetry/edema; 
2+ bilateral symmetric radial pulses; no calf swelling/TTP/cord [47].
6 CT HEAD. Technique: Contiguous noncontrast transaxial images from the vertex to the skull base 
were obtained. Estimated phantom dose: CTDIvol (mGy): 29 DLP (mGy-cm): 501. Consider follow-up 
limited brain FDG-PET evaluation (PET scan) to work up dementia, if clinically indicated.
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and subjects with AD because portions of the lateral ventricles are adjacent to the 
medial temporal lobe (MTL), structures that atrophy notably in the preclinical 
stages of dementia [38, 48]. Nestor et al. [49] even hypothesize that ventricular 
dilatation after 6 months would differentiate normal aging, MCI, and MCI to AD 
progressors and be a more sensitive measure of disease progression than cognitive 
scores. For example, they found subjects with AD had a 60% greater ventricular 
enlargement than subjects with MCI and a fourfold enlargement compared with 
normal aging as measured over a 6-month interval. Jack et al. [50] argue that 
hemispheric atrophy rates, measured by ventricular enlargement, correlate more 
strongly with changes on cognitive tests than medial temporal lobe (MTL) atrophy 
rates and capture significant variation between subjects with MCI and AD [37, 39]. 
The rate of ventricular volume change is also highly correlated with an increase in 
senile plaques and neurofibrillary tangles [51].
In AR’s case such ventricle enlargement was, in fact, a sensitive measure of 
disease progression. Six months later in his follow-up visit (12/18), AR’s Slums score 
had dropped by 4 points to 20/30, and his AD8 score increased by 1 point to 1/8. 
Even more disease progression was evident in cognitive measures of his short-term 
memory: AR scored 4/8 in story recall and had a 0/5 recall of objects 5 minutes 
later [47]. At this point in time, December 2012, AR’s neurologist diagnosed him 
with early AD. He noted: “Impression and plan: It is now clear that this is early 
Alzheimer’s. Will begin Aricept. Gave information on Alzheimer’s disease and 
referral number of our incredibly skilled and compassionate memory clinical social 
worker. Follow up on 3–4 months [47].”
4.2  3 ½ years after diagnosis: 3 years on intranasal insulin: still looks more like MCI
AR, in conjunction with his family, made the decision to begin intranasal 
insulin therapy in June 2013, 6 months after his 12/12 AD diagnosis. At this point, 
his MMSE score was 24 (3/13), and his word recall after 10 minutes was 0/9 (3/13) 
[2]. The patient’s functional abilities had also markedly deteriorated from a year 
previous at his 5/12 MCI diagnosis. AR could no longer manage his finances or his 
medical treatments and could no longer drive. His family also noticed the develop-
ment of significant social and linguistic withdrawal, irritability, and flattened 
affect ([1]:331–333). For example, AR expressed very little positive emotion upon 
seeing his daughter and granddaughter at the airport after a 6-month separation. 
Furthermore, he was unable to participate in conversations or even access anything 
about himself such as how he was feeling, often remaining silent for extended 
periods of time, and withdrawing from social engagement ([1]:331–333).
The patient’s family began compassionate use of intranasal therapy (6/13) at twice 
daily for AR (20 IU per dose). Over the subsequent 6–8 months of treatment, they 
noticed a marked return of pragmatic functioning, an increase in social and linguistic 
participation (even returning to telling and understanding jokes), self-awareness, and 
decreased irritability ([1]:333–35). AR himself reported just 2 days after beginning 
therapy that his head hurt less, spontaneously holding his head with his hand and 
stating to his daughter: “Oh, it is like I have had a terrible headache for a long time.”
A return of meaningful linguistic interaction after intranasal insulin therapy 
and a stabilization of the further deterioration were also noted by other patient’s 
family members after several months. This stabilization was reflected in his 2014 
and 2015 neuropsychological battery of tests. These cognitive tests revealed a 
marked slowing of annual percent decline in executive function and visuospatial 
scores compared with average annual declines [2, 31]. AR also was able to use and 
respond affectively to humor in conversations, related areas of the brain typically 
associated with significant deterioration in AD progression [52].
Who Wants to Retire and Who Can Afford to Retire
8
A CT scan was taken on AR in October 2016, just over 3 years after the patient 
began receiving intranasal therapy (Figure 1a and b). Again, the overall neurolo-
gist’s impression was “age-related volume loss.” The record reads:
Comparison: “Comparison is made with 05/17/2012. There is no evidence of 
intracranial hemorrhage, mass, mass effect, large infarct or midline shift. Prominence 
of the ventricles and sulci are noted, likely age-related volume loss. Scattered periven-
tricular white matter hypodensities are noted, most commonly seen with small vessel 
ischemic changes. Vascular calcifications are noted. Partial opacification of the ethmoid 
and sphenoid sinuses noted. Bones are unremarkable. Impression: No evidence of acute 
intracranial process. Age-related volume loss. Likely small vessel ischemic changes [47].”
This diagnosis of “age-related volume loss” after 3 years receiving intranasal 
insulin suggests some positive effects of extended therapy. AR’s neurologist noted 
in his 10/16 comments that the patient was: “alert and oriented” with “5/5 strength 
in all 4 extensions with full distal sensation; no saddle anesthesia; 2+ symmetric 
reflexes throughout and ambulates without difficulty [47].”
Figure 1a and b shows evidence of AD disease stage progress. For example, in 
his 10/16 notes, AR’s neurologist comments on the “prominence of the ventricles 
and sulci” which are more enlarged (the ventricles) and deeper (the sulci in 
the frontal lobe) (Figure 1a) than AR’s 5/12 MCI diagnosis CT scan (Figure 2). 
Furthermore, AR’s memory was very uneven; he stated that he quit smoking when 
he was 30 years old but did not remember his daughter who lived out of state.
Further clarification of the positive effects of intranasal insulin therapy at 3 
½ years after his AD diagnosis can be observed comparatively. Figure 3 shows a 
structural MRI of the typical progressive atrophy (of medial temporal lobes and hip-
pocampus) in an older cognitively normal (CN) subject, an amnestic mild cognitive 
impairment (aMCI) subject, and an Alzheimer’s disease (AD) subject. In this disease 
progression from MCI to mild AD, the hippocampus of the subject in Figure 3 shows 
marked atrophy as indicated by the white arrows. Hippocampal atrophy, especially 
left volumes, and its contribution to memory decline in the process of Alzheimer’s 
disease have been often described and are widely accepted [53, 54].
In contrast, AR’s CT scan (Figure 1a) shows a hippocampus size that is still rela-
tively robust. As indicated by the white arrow in Figure 1a, AR’s left hippocampus 
is similar to that of the patient in Figure 3 at MCI disease stage. Figure 1a and b also 
shows significantly less overall frontal cortex atrophy, medial temporal lobe atro-
phy, and occipital lobe atrophy as compared with disease progression of the MCI to 
Figure 1. 
(a) and (b): CT scans of patient AR, 10/16.
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AD patient (Figure 3). These are significant positive effects of extended intranasal 
insulin as illustrated in AR’s 10/16 CT scan.
A return of meaningful linguistic interaction after intranasal insulin therapy 
and a stabilization of AR’s executive functioning test scores also reflect his neurolo-
gist’s overall interpretation of “age-related” (vs AD disease progression related) 
volume loss in his 10/16 CT scan. AR’s executive functioning capacities at year 4 
after AD diagnosis include still being able to actively watch a TV series in several 
45-minute episodes. In addition, on one occasion, when a scratched DVD disk 
caused the episode to pause, AR was able to immediately alert his daughter of the 
need to fix the problem. This demonstrates that AR was actively paying attention 
[2]. Prolonged attention span was found across patients with Phelan-McDermid 
syndrome after 1 year receiving intranasal insulin [55].
Another patient diagnosed with mild AD improved his executive functioning area 
scores (immediate recall, delayed free recall, and animal recall scores) after 8 months 
receiving intranasal insulin [2]. As Sperling et al. [56] note, AD causes considerable 
damage to the neurobiological substrate of episodic memory, the hippocampal-
entorhinal complex (located in the medial temporal lobes) early in the course of the 
disease. After several years receiving intranasal insulin therapy, the patient continued 
Figure 2. 
CT scan of patient AR, 5/12.
Figure 3. 
Structural MRI of the typical progressive atrophy (of medial temporal lobes and hippocampus) in an older 
cognitively normal (CN) subject, an amnestic mild cognitive impairment (aMCI) subject, and an Alzheimer’s 
disease (AD) subject.
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to demonstrate capabilities in visual processing skills (occipital and parietal lobe 
functioning) as well as improvements in executive functioning under targeted 
therapy. At 3 years, he had returned to being able to ski (2019) after having lost the 
ability to manage his finances, shop, or independently go to doctor’s visits [2].
4.3  5 ½ years after AD diagnosis and 5 years on insulin therapy: less atrophy of 
occipital and thalamic structures
At year 5 ½ after AD diagnosis and at 5 years receiving intranasal insulin therapy 
(12/17–12/18), AR was still able to inferentially reason. He was also fully ambulatory, 
eating with the mild AD patients at his nursing home, and looked at books and TV 
while paying attention to both. His visual skills were also still intact. For example, one 
day AR was walking independently back to his room with his daughter and headed 
toward a large automatic opening and closing door to the Alzheimer wing which 
was being held open by a staff member. AR immediately turned to his daughter and 
asked: “Can we go through?” His daughter responded: “Yes.” Then AR was able to 
remember, proceeded to analyze contextual information and to simultaneously warn 
her of possible impending danger, telling her: “Hurry up. It closes fast” [3].
Figure 4 is AR’s CT scan at 5 years receiving intranasal insulin therapy (5 
½ years after AD diagnosis) (4/18). Figure 5a and b presents subcortical segmenta-
tion of MRI scans after boundary correction of a subject classified as MCI (4a) and 
of a subject diagnosed with probable Alzheimer’s disease (4b) [26].
Consistent with our hypothesis that extended therapeutic usage should slow AD 
disease progression, AR’s 4/18 CT scans demonstrate that his occipital lobe does 
not show a significant shrinkage of gray matter volume (indicated by black arrow, 
Figure 4). Similarly, AR’s thalamus, indicated by the yellow arrow (Figure 4), is 
also not as atrophied in terms of volume loss as the AD patient (Figure 5b) despite 
his significant frontal volume loss and lateral ventricle enlargement consistent with 
late-stage AD [50].
AR’s retained volume in the occipital and thalamic subcortical structures supports 
previous findings that intranasal insulin directly reaches the occipital cortical brain 
regions and the thalamus in older adults [10]. These results suggest such enhanced 
insulin action in these brain areas can, in fact, slow AD disease progression.
Figure 4. 
CT scan of patient AR, 4/18.
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Figure 6a and b demonstrates how AR clearly shows signs of advanced AD by 
4/18. AR’s neurologist noted of his 4/18 CT scan:
“Lateral ventricles are enlarged with disproportionate enlargement of the frontal 
horns. Temporal horns are both markedly enlarged, more so on the right. Third 
ventricle is moderately enlarged. Basel cisterns are enlarged, as are the sylvian 
fissures. Overall, findings are compatible with generalized volume loss, with dis-
proportional frontal and temporal lobe volume loss. This includes medial temporal 
lobe volume loss with likely considerable hippocampal volume loss especially on the 
right. Sulci are not symmetrical on both sides [47].”
Figure 5. 
(a) and (b): subcortical segmentation of MRI scans, after boundary correction, of a subject classified as MCI 
(a) and of a subject diagnosed with probable Alzheimer’s disease (b) (sagittal view) [26].
Figure 6. 
(a) and (b): CT scans of patient AR, 4/18.
Who Wants to Retire and Who Can Afford to Retire
12
Yet, as (again) compared with probable AD (Figure 7b), AR demonstrates less 
overall volume loss even with respect to the medial temporal lobe. Furthermore, in AR’s 
case, left hippocampus atrophy is less pronounced than right (Figure 6a and b). This 
is also a significant finding because, as de Jong et al. [26] found in their Alzheimer’s 
disease group, volume reduction of the left hippocampus, putamen, and thalamus 
formed the strongest predictors for declining cognitive performance in Alzheimer’s 
disease progression.
5. Discussion
The potential of intranasal insulin to curb the development and progression of 
AD [57] is by avoiding decreases in cerebral glucose metabolic rate within a complex 
neuronal network which comprises the hypothalamus, hippocampus, thalamus, and 
cortical brain structures. A series of CT scan results of a patient receiving extended 
administered intranasal insulin usage shows delayed atrophy of key areas of the 
brain associated with cognitive, visual, executive, and pragmatic functioning as 
compared to disease progression in MCI to AD patients not receiving therapy. These 
findings, particularly those that demonstrate slowed atrophy of the thalamus and 
occipital lobe, strongly suggest that extended intranasal insulin treatment might 
slow disease progression by reducing some areas of neuronal atrophy in the (thala-
mus) cortico-pulvinar projection system [18] associated with the anomia typical of 
late-stage AD [58, 59]. They also highlight the importance of thalamic stimulation on 
language and cognition and the ability of the preservation of nuclei within the thala-
mus to regulate the transmission of information to the cortex and between cortical 
areas [21]. The reduced atrophy of the occipital lobes in this patient on extended 
intranasal insulin therapy is also significant because lesion studies have shown that 
the pulvinar is critically involved in visual perception, attention, and visually guided 
behavior [21], which can include directing visual attention to a cued location.
The slowing of atrophy of the thalamus is also consistent with the hypothesized 
medial pathway of insulin [2, 3, 60] in which the thalamus is reached via the olfac-
tory tubercle. Future research is required to refine precisely how intranasal insulin 
promotes glucose utilization in these neuronal networks, i.e., through changes in 
hippocampal synaptic plasticity and/or by increasing synapse density and dendritic 
plasticity in structures that process visual input ([61]:216).
Future follow-up studies are needed to explore how intranasal insulin’s poten-
tial effectivity for reducing transition rates from amnestic MCI to AD is related 
to preserving those neurological structures associated with pragmatic tasking. 
Figure 7. 
(a) and (b): subcortical segmentation of MRI scans, after boundary correction, of a subject classified as MCI 
(a) and of a subject diagnosed with probable Alzheimer’s disease (b) (axial view) [26].
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Specifically, additional studies are required consisting of mapping out the bulk 
flow of intranasal insulin along the olfactory and trigeminal pathways between the 
nasal passages and the CNS into deeper structures within the medial temporal lobe 
(MTL) ([45, 62]:491). The region of the MTL showing the greatest atrophy in mild 
cognitive impairment is the entorhinal cortex, which is precisely part of the para-
hippocampal gyrus and is the same region that has been postulated by Braak and 
Braak [40] to be the site where AD pathology is first expressed.
Additional practical studies are necessary to understand the relationship between 
the olfactory system and the delivery route of intranasal insulin on such hippocam-
pal structures within the MTL to further elucidate the potential of intranasal insulin 
therapy. AR’s continuing pragmatic abilities including sarcastic utterances, utilizing 
empathic tone and pragmatic discourse markers [3] 6 years after AD diagnosis and 
5 ½ years on intranasal insulin, point toward the partial effect of intranasal insulin 
on deeper hippocampal brain structures. The right parahippocampal gyrus, for 
example, has functions beyond the contextualizing of visual background stimuli and 
identifying social context such as the inclusion of paralinguistic elements of verbal 
communication resulting in the ability to employ sarcasm [63]. As Smith [43] notes:
Many years (up to 50) before the symptoms (of AD) occur, neurofibrillary 
tangles start to form in neurons in the parahippocampal gyrus. At some stage, this 
process is exacerbated, and many projection neurons in the MTL then start to die, 
leading to atrophy of the lobe and to early signs of memory deficits. Once denuded 
of their input from the MTL, neurons in the target areas of neocortex show reduced 
activity, leading to slower metabolism and a fall in local blood flow. They will no 
longer function properly in the neural networks underlying higher cognition [64].
The findings in this chapter also illustrate, on a brain circuitry level, AR’s other 
continued pragmatic capacities even with late-stage AD [2, 3]. Several weeks before 
his death from a post-hip surgery-related heart attack, AR was still able to employ 
a bodily related metaphor: “I am tired. It seems like that is all I say. What a pain in 
the ass that is.” This statement involves the capacity to abstract and inhibit literal 
interpretation, both of which are associated with executive functioning tasks. Other 
linguistic evidence of AR’s preserved pragmatic competence even 5.5 years after his 
AD diagnosis include telling jokes and using humor to assert autonomy [1–3]. The 
capacity to detect, understand, and respond to humor deteriorates significantly in 
the progression of AD [65]. Scholarship on the neural basis of humor processing 
precisely suggests that humor engages a core network of cortical and subcortical 
structures, including temporo-occipito-parietal areas involved in detecting and 
resolving incongruity [66]. The temporo-parietal junction incorporates information 
from the thalamus, among other systems.
Treatment-induced improvements in neuronal activity in the thalamus and 
occipital and parietal lobes can bring moderate to significant improvements in 
communication exchanges with caregivers, thereby reducing the AD patient’s 
social and communicative isolation, lessen caregiver stress, and improve execu-
tive functioning. Furthermore, AR’s annual, standard blood tests did not reveal 
abnormalities or indicators of chronic intranasal insulin therapy leading to 
(further) desensitization of his brain insulin signaling [67] a concern expressed in 
the literature [57].7
The results contained in this paper are the first published CT scans of a 
patient receiving extended intranasal insulin use. Begun at early MCI diagnosis, 
the extended use of intranasal insulin could substantially impact sites along the 
7 Future studies can measure this potential through recent exosome biomarker tests derived from blood, 
plasma, and serum for the detection of brain insulin signaling resistance [68, 69].
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olfactory pathway (hypothesized to be affected early on in AD).8 This could 
potentially arrest the further spread of the disease process in the involvement of 
the hippocampus, areas of the neocortex in the parietotemporal and frontal lobes, 
as well as hypothalamic inflammation linked to age and disease-related declines 
in insulin sensitivity [4, 46]. One patient after 8 months of intranasal insulin was 
administered a series of pre- and post-therapy neuropsychological tests, including 
visuospatial skills, visual spatial ability, visual working memory, and executive 
functioning after beginning intranasal insulin [2]. Eight months later, his neurolo-
gist concluded that: “There was about a two-year reversal of cognitive impairment 
while receiving intranasal insulin, going from mild dementia to mild cognitive 
impairment [3].” A return to MCI from early AD is a significant therapeutic 
achievement that deserves further application and investigation.
Additional materials
Several previous studies on 153 MCI and AD patients involved in the short- 
(4 months) and medium-term (12 months) administration of intranasal insulin 
using the ViaNase device to deliver the drug confirm the findings of the preservation 
of caregiver-rated functional ability in MCI and AD patients. The first randomized, 
placebo-controlled pilot study of ViaNase delivered intranasal insulin consisted of 
104 adults with amnestic mild cognitive impairment (n = 64) or mild to moderate 
AD (n = 40), all of whom were treated with 20 and 40 IU daily dosages of intranasal 
insulin for 4 months (9). The mean patient age was 71 years old, and the mean 
3MSE score was 83.7–84.3 [20 IU/40 IU]. 50–57% were positive for the high-risk 
apolipoprotein E epsilon-4 allele. The following results were reported: “Treatment 
with 20 IU of insulin improved delayed memory (P < .05), and both doses of insulin 
(20 and 40 IU) preserved caregiver-rated functional ability (P < .01). Both insulin doses 
also preserved general cognition as assessed by the ADAS-cog score for younger 
participants and functional abilities as assessed by the ADCS-ADL scale for adults 
with AD (P < .05). Cerebrospinal fluid biomarkers did not change for insulin-treated 
participants as a group, but, in exploratory analyses, changes in memory and function 
were associated with changes in the Aβ42 level and in the tau protein-to-Aβ42 ratio in 
cerebrospinal fluid. Placebo-assigned participants showed decreased fludeoxyglucose 
F 18 uptake in the parietotemporal, frontal, precuneus, and cuneus regions and 
insulin-minimized progression.” The second placebo-controlled study of ViaNase 
delivered intranasal insulin administration consisted of 49 of 289 patients with mild 
cognitive impairment (MCI) or mild Alzheimer’s disease (AD) who were randomized 
to receive either insulin or placebo daily for 12 months [70].9 This was a phase 2/3 
trial at 26 US sites and a change in cognitive function from baseline to 12 months 
served as the primary endpoint, with the primary outcome measuring the Alzheimer’s 
8 In the olfactory system, the sites that are affected include the anterior olfactory nucleus, the uncus, and 
the medial group of amygdaloid nuclei—all receives fibers directly from the olfactory bulb ([69]:4534).
9 Assessments were made at baseline and at 3-month intervals until the end of the study, when 
participants were offered open-label insulin treatment for another 6 months. The other 240 patients 
used a different device (Precisions Olfactory Delivery [POD]) which failed to produce any difference 
in outcome on the ADAS-Cog 12 measure at 12 months with the placebo group. Both POD and placebo 
groups increased by about 4 points on the ADAS-Cog 12 measure, indicating worsening. Nor were 
there any changes in any other Alzheimer-related biomarkers like amyloid-beta 40 and 42, total tau, or 
phosphorylated tau (Clinical Neurology News 12/4/18:2). The model is controlled for age, sex, genetic 
risk status, and investigation site. Patients were a mean of 71 years old, with a mean Mini Mental State 
Exam score of 25. Around 42% were positive for the high-risk apolipoprotein E epsilon-4 allele.
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Disease Assessment Scale-Cognition measure (ADAS-Cog 12). The ViaNase delivered 
intranasal insulin slowed the annual progress of cognitive decline by 50%—or only a 2.5-
point decline per patient on the ADAS-Cog12 versus the 5-point decline per patient of 
the placebo group. This significant “separation was evident at 3 months and continued 
to widen over the course of the [12 month] study” [71].
The finding in this chapter of the reduction of caregiver stress after the longer-
term administration (3 plus years) of intranasal insulin is also evident from 
qualitative findings from an open-label study of 22 MCI and AD patients on the 
compassionate use of intranasal insulin.10 These patients displayed, before ViaNase 
delivered treatment, significant symptoms of social and linguistic withdrawal, 
flattening of affect, and irritability, as well as moderate to high levels of family-
reported caregiver stress [1–3, 60]. Several publications also extensively document 
treatment-mediated improvements in language, visuospatial, and, in particular, 
executive functioning test scores of patients at moderate AD and an early MCI 
patient (5) and a return of pragmatic competence in the areas of jokes, self-expres-
sion, and empathy in early and moderate AD and MCI patients [1, 60]. Over 90% 
of caregivers of the 22 compassionate use patients also reported moderate to very 
strong reductions in caregiver stress after 1 year of intranasal insulin administration 
to their family members [1, 60, 73, 74].
10 These MCI and AD patients live in naturalistic settings (2011–present) and provide linguistic 
evidence on phenomena as they naturally occur, i.e., they provide conversational data for the case study 
methodology as used by sociologists for the purpose of theory development and building. Hamilton [72] 
found that it is only in such conversations that it is possible to describe the full range of communicative 
competence of a person with AD.
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